iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
February 27, 2020 01:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers – First patient enrolled in dose escalation portion of...
OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
November 02, 2017 16:05 ET
|
OncoMed Pharmaceuticals, Inc.
Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017
April 03, 2017 13:00 ET
|
OncoMed Pharmaceuticals, Inc.
WASHINGTON and REDWOOD CITY, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing...